Research funder · Australia
Therapeutic Innovation Australia
- Grants since 2016
- 310
- Awarded, last 5 years (where amounts are published)
- —
- Funded works, last 5 years
- 146
- Funded works, all time
- 282
Grants
2026
Development of automated manufacture of hair follicle-derived neuroprecursors for GLP-Tox IND-enabling studies
2026
Novel disease-modifying approach to treat pulmonary hypertension
2026
Discovery of selective inhibitors for fibrosis
2026
Identifying compounds that protect against anthracycline induced heart damage
2026
Developing METTL5 Inhibitors for the treatment of paediatric neuroblastoma and adult solid tumours
2026
Tumour infiltrating lymphocyte therapy for appendiceal cancer
2026
Synthesis of novel peptide mimics for use as anti-fibrotic agents
2026
Hit identification using DEL for the development of small molecule targeted treatment of osteosarcomas
2026
Development of new cancer therapeutics targeting the nucleoli
2026
Developing fucosyltransferase inhibitors as treatments for rare leukaemia
2026
Development of a mRNA nanoparticle formulation for low back pain treatment
2026
Breaking ceftriaxone resistance in Neisseria gonorrhoeae using an inhibitor of lipid A phosphethanolamine transferase (EptA)
2026
Iterative design of selective Type II JAK2 Inhibitor for superior management of myelofibrosis
2026
Synthesis and characterisation of Ag2S quantum dots and conjugation to insulin at CSIRO
2026
Development of endothelial targeted-CD39 as a novel treatment for micro circulatory thrombosis in stroke and global brain ischaemia.
2026
mRNA-LNP vaccines targeting multiple stages of the malaria parasite lifecycle
2026
Development of novel therapeutics for targeted therapy of triple negative breast cancer
2026
Advanced Optimisation of Antivirulence Compounds Against Bacterial Pathogens
2026
Development of an Inhaled siRNA Therapeutic Targeting TNF-α for Pulmonary Inflammation
2026
Pharmacokinetics of Next-Generation Iron Chelators
2026
Peripherally Restricted NPSR1 Antagonist in Endometriosis
2026
Assessing the manufacturability of a new probiotic species
2026
RNA-Based Nanotechnology for the Control of Leishmania
2026
Developing the first multi-species malaria vaccine to provide worldwide protection
2026
Development of a novel treatment option for post-sepsis acute lung injury (ALI)
2026
Identifying New Targets to Treat Metabolic Disease
2026
Innovative IBD biologics inspired by host-parasite coevolution
2026
Targeting FtsY for a new class of antibiotics
2026
Bi-specific proteins for the enhancement of pluripotent stem cell derived heart muscle grafts
2026
Engineering IgG-like ACE2 antivirals against future pathogenic coronavirus events
2026
Studies of Bacterial Resistance Induced by Cannabidiol (CBD)
2026
Development of drug candidates against drug resistant bacteria
2026
Phase II Amnion Cell Therapy in Ischemic Stroke
2026
Analytical and bioanalytical development of pixatimod (ZU545/PG545)- a clinical candidate for cancer with anti-viral and anti-inflammatory properties - to support clinical testing for Covid-19”
2026
Pharmacokinetics and distribution of novel non-steroidal asthma drugs
2026
Commercial scale up of CMV and EBV specific T-cell manufacturing
2026
Developing new therapies to treat ADAR1 mutant disease.
2026
Overcoming the heterogeneity of cancer antigen expression with an mRNA vaccine and precision LNP delivery.
2026
Scaling up the manufacture of an mRNA vaccine for the prevention of urinary tract infection
2026